France says it will start administering Pfizer's coronavirus antiviral drug this week, the first pill for treating COVID-19 approved in the 27-nation EU.
The country is still reporting among the world's highest per-capita daily infections, but virus-related critical care hospitalizations are easing, and the French government on Wednesday started lifting restrictions related to the surge in omicron cases.
Masks are now no longer required outdoors in France, large crowds are again allowed in concerts and sports venues and a government order to work from home part-time has been lifted.
Meanwhile, France has received its first 10,000 doses of the Pfizer drug Paxlovid and they will be available in pharmacies starting Friday, the Health Ministry said Wednesday. It says it's the first European Union country to start providing the treatment since it won regulatory approval last week.
It will be given to adults with symptoms who don't require oxygen and who are at higher risk of severe disease, according to European Medicines Agency guidelines. Supplies of the drug remain limited worldwide.
The EMA last week recommended that Paxlovid be authorised for use, saying it could help people infected with COVID-19 avoid more serious disease and being hospitalised. The drug was cleared by regulators in the US and Britain in December.
An antiviral pill from Merck also is expected to soon be authorised. Both drugs are expected to be effective against omicron because they do not target the spike protein where most of the variant's worrisome mutations reside.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)